卵巢癌的预后生物标志物。
Prognostic biomarkers in ovarian cancer.
机构信息
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
出版信息
Cancer Biomark. 2010;8(4-5):231-51. doi: 10.3233/CBM-2011-0212.
Abstract
Epithelial ovarian cancer (EOC) remains the most lethal gynecological malignancy despite several decades of progress in diagnosis and treatment. Taking advantage of the robust development of discovery and utility of prognostic biomarkers, clinicians and researchers are developing personalized and targeted treatment strategies. This review encompasses recently discovered biomarkers of ovarian cancer, the utility of published prognostic biomarkers for EOC (especially biomarkers related to angiogenesis and key signaling pathways), and their integration into clinical practice.
摘要
尽管在诊断和治疗方面取得了几十年的进展，但上皮性卵巢癌 (EOC) 仍然是最致命的妇科恶性肿瘤。利用发现和应用预后生物标志物的快速发展，临床医生和研究人员正在开发个性化和靶向治疗策略。本文综述了最近发现的卵巢癌生物标志物、已发表的 EOC 预后生物标志物的实用性（特别是与血管生成和关键信号通路相关的生物标志物）及其在临床实践中的整合。
相似文献
1
Prognostic biomarkers in ovarian cancer.卵巢癌的预后生物标志物。
Cancer Biomark. 2010;8(4-5):231-51. doi: 10.3233/CBM-2011-0212.
2
miRNAs as prognostic and therapeutic tools in epithelial ovarian cancer.微小RNA作为上皮性卵巢癌的预后和治疗工具
Biomark Med. 2015;9(3):241-57. doi: 10.2217/bmm.14.108.
3
Increased expression of protein kinase CK2α correlates with poor patient prognosis in epithelial ovarian cancer.蛋白激酶CK2α的表达增加与上皮性卵巢癌患者的不良预后相关。
PLoS One. 2017 Mar 29;12(3):e0174037. doi: 10.1371/journal.pone.0174037. eCollection 2017.
4
Identification of novel candidate biomarkers of epithelial ovarian cancer by profiling the secretomes of three-dimensional genetic models of ovarian carcinogenesis.通过分析卵巢癌发生三维遗传模型的分泌组来鉴定上皮性卵巢癌新的候选生物标志物。
Int J Cancer. 2015 Oct 15;137(8):1806-17. doi: 10.1002/ijc.29197. Epub 2015 Jul 2.
5
The role of tumour-associated MUC1 in epithelial ovarian cancer metastasis and progression.肿瘤相关MUC1在上皮性卵巢癌转移和进展中的作用。
Cancer Metastasis Rev. 2013 Dec;32(3-4):535-51. doi: 10.1007/s10555-013-9423-y.
6
Overexpression of trophoblast cell surface antigen 2 as an independent marker for a poor prognosis and as a potential therapeutic target in epithelial ovarian carcinoma.滋养层细胞表面抗原2的过表达作为上皮性卵巢癌预后不良的独立标志物及潜在治疗靶点。
Int J Exp Pathol. 2016 Apr;97(2):150-8. doi: 10.1111/iep.12174. Epub 2016 Apr 29.
7
Epigenetic biomarkers in epithelial ovarian cancer.上皮性卵巢癌的表观遗传学标志物。
Cancer Lett. 2014 Jan 28;342(2):257-63. doi: 10.1016/j.canlet.2011.12.036. Epub 2012 Jan 12.
8
Expression of Placenta Growth Factor Is Associated with Unfavorable Prognosis of Advanced-Stage Serous Ovarian Cancer.胎盘生长因子的表达与晚期浆液性卵巢癌的不良预后相关。
Tohoku J Exp Med. 2018 Apr;244(4):291-296. doi: 10.1620/tjem.244.291.
9
AEG -1 overexpression: a novel indicator for peritoneal dissemination and lymph node metastasis in epithelial ovarian cancers.AEG-1 过表达：上皮性卵巢癌腹膜播散和淋巴结转移的新指标。
Int J Gynecol Cancer. 2011 May;21(4):602-8. doi: 10.1097/IGC.0b013e3182145561.
10
Down-regulated miR-22 as predictive biomarkers for prognosis of epithelial ovarian cancer.下调的miR-22作为上皮性卵巢癌预后的预测生物标志物。
Diagn Pathol. 2014 Sep 26;9:178. doi: 10.1186/s13000-014-0178-8.
引用本文的文献
1
The prognostic role of systemic inflammatory markers in apparent early-stage ovarian cancer.全身炎症标志物在早期卵巢癌中的预后作用。
Int J Clin Oncol. 2023 Feb;28(2):314-320. doi: 10.1007/s10147-022-02272-z. Epub 2022 Nov 22.
2
Combined BRCA2 and MAGEC3 Expression Predict Outcome in Advanced Ovarian Cancers.BRCA2与MAGEC3联合表达可预测晚期卵巢癌的预后。
Cancers (Basel). 2022 Sep 28;14(19):4724. doi: 10.3390/cancers14194724.
3
DAGBagM: learning directed acyclic graphs of mixed variables with an application to identify protein biomarkers for treatment response in ovarian cancer.DAGBagM：学习混合变量的有向无环图及其在卵巢癌治疗反应中识别蛋白质生物标志物的应用。
BMC Bioinformatics. 2022 Aug 5;23(1):321. doi: 10.1186/s12859-022-04864-y.
4
Applications of Proteomics in Ovarian Cancer: Dawn of a New Era.蛋白质组学在卵巢癌中的应用：新时代的曙光。
Proteomes. 2022 May 9;10(2):16. doi: 10.3390/proteomes10020016.
5
Beyond the snapshot: optimizing prognostication and prediction by moving from fixed to functional multidimensional cancer pathology.超越快照：通过从固定的多维癌症病理学转向功能多维癌症病理学来优化预后和预测。
J Pathol. 2022 Jul;257(4):403-412. doi: 10.1002/path.5915. Epub 2022 May 23.
6
Prognostic utility of the ovarian cancer secretome: a systematic investigation.卵巢癌分泌组的预后效用：系统研究。
Arch Gynecol Obstet. 2022 Sep;306(3):639-662. doi: 10.1007/s00404-021-06361-8. Epub 2022 Jan 27.
7
Development of a novel transcription factors-related prognostic signature for serous ovarian cancer.新型转录因子相关预后标志物预测浆液性卵巢癌。
Sci Rep. 2021 Mar 30;11(1):7207. doi: 10.1038/s41598-021-86294-z.
8
CircRNA FGFR3 induces epithelial-mesenchymal transition of ovarian cancer by regulating miR-29a-3p/E2F1 axis.环状 RNA FGFR3 通过调控 miR-29a-3p/E2F1 轴诱导卵巢癌细胞上皮-间充质转化。
Aging (Albany NY). 2020 Jul 15;12(14):14080-14091. doi: 10.18632/aging.103388.
9
Rho GTPases in Gynecologic Cancers: In-Depth Analysis toward the Paradigm Change from Reactive to Predictive, Preventive, and Personalized Medical Approach Benefiting the Patient and Healthcare.妇科癌症中的Rho GTP酶：对从反应性医疗模式向预测性、预防性和个性化医疗模式转变的深入分析，这将使患者和医疗保健受益。
Cancers (Basel). 2020 May 20;12(5):1292. doi: 10.3390/cancers12051292.
10
Integrated multiomic predictors for ovarian cancer survival.卵巢癌生存的综合多组学预测因子。
Carcinogenesis. 2018 Jul 3;39(7):860-868. doi: 10.1093/carcin/bgy055.
本文引用的文献
1
Enhancer of zeste homolog 2 promotes the proliferation and invasion of epithelial ovarian cancer cells.增强子结合锌指蛋白 2 促进上皮性卵巢癌细胞的增殖和侵袭。
Mol Cancer Res. 2010 Dec;8(12):1610-8. doi: 10.1158/1541-7786.MCR-10-0398. Epub 2010 Nov 29.
2
Circulating free DNA and p53 antibodies in plasma of patients with ovarian epithelial cancers.卵巢上皮癌患者血浆中循环游离 DNA 和 p53 抗体。
Ann Oncol. 2011 May;22(5):1133-1140. doi: 10.1093/annonc/mdq584. Epub 2010 Nov 23.
3
Prognostic effect of epidermal growth factor receptor gene mutations and the aberrant phosphorylation of Akt and ERK in ovarian cancer.表皮生长因子受体基因突变和 Akt、ERK 异常磷酸化对卵巢癌的预后影响。
Cancer Biol Ther. 2011 Jan 1;11(1):50-7. doi: 10.4161/cbt.11.1.13877.
4
Excision repair cross-complementation group 1 protein overexpression as a predictor of poor survival for high-grade serous ovarian adenocarcinoma.切除修复交叉互补基因 1 蛋白过表达可预测高级别浆液性卵巢腺癌患者生存不良。
Gynecol Oncol. 2010 Nov;119(2):325-31. doi: 10.1016/j.ygyno.2010.07.018. Epub 2010 Aug 21.
5
Regulation of tumor angiogenesis by EZH2.EZH2 对肿瘤血管生成的调控。
Cancer Cell. 2010 Aug 9;18(2):185-97. doi: 10.1016/j.ccr.2010.06.016.
6
HER3 mRNA as a predictive biomarker in anticancer therapy.HER3 mRNA 作为癌症治疗的预测性生物标志物。
Expert Opin Biol Ther. 2010 Sep;10(9):1343-55. doi: 10.1517/14712598.2010.512003.
7
Mass spectrometry-based protein biomarker discovery: solving the remaining challenges to reach the promise of clinical benefit.基于质谱的蛋白质生物标志物发现：解决剩余挑战以实现临床获益的前景
Clin Chem. 2010 Oct;56(10):1641-2. doi: 10.1373/clinchem.2010.146142. Epub 2010 Jul 21.
8
Increased ERCC1 protein expression is associated with suboptimal debulking in advanced epithelial ovarian cancer.ERCC1 蛋白表达增加与晚期上皮性卵巢癌的减瘤不充分相关。
Anticancer Res. 2010 Jun;30(6):2447-52.
9
Cancer statistics, 2010.癌症统计数据，2010 年。
CA Cancer J Clin. 2010 Sep-Oct;60(5):277-300. doi: 10.3322/caac.20073. Epub 2010 Jul 7.
10
Ovarian cancer biomarker screening: still too early to tell.卵巢癌生物标志物筛查：目前下结论还为时过早。
Womens Health (Lond). 2010 Jul;6(4):487-90. doi: 10.2217/whe.10.33.
Zotero 插件